AstraZeneca to invest US$30M in Chennai expansion

INDIA — AstraZeneca India Private Limited (AZIPL), the Global Capability Centre (GCC) of AstraZeneca, has announced an investment of 250 crore rupees (US$30 million) to expand its Global Innovation and Technology Centre (GITC) in Chennai, Tamil Nadu.

This substantial investment encompasses nearly 1,300 roles focused on driving innovation, enhancing efficiency, and streamlining operations across the company globally.

The expanded facility was inaugurated today in a ceremony officiated by the Honourable Minister of Industries Tamil Nadu, Dr. T.R.B. Rajaa, British Deputy High Commissioner to India, Ms. Christina Scott CMG, AstraZeneca Vice President for Asia Area Ms. Sylvia Varela, along with AstraZeneca’s leadership team in the country.

The investment marks a significant milestone in AstraZeneca’s growth story in India as it celebrates its 45th year in the country this month.

With the highly skilled roles to be brought in by 2025, the expanded GITC will propel the company’s vision to leverage technologies such as enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics to shape healthcare outcomes.

Speaking during the inauguration, Mr. Siva Padmanabhan, Managing Director of AstraZeneca India Private Limited (AZIPL), noted that AstraZeneca has been evolving its technologies constantly to stay ahead of the curve in the healthcare and pharmaceutical industries, thereby better serving their patients in the countries where they operate.

He emphasized their deep investment in infusing the best of technology and innovation practices into the healthcare ecosystem.

Dr. Sanjeev Panchal, Managing Director & Country President of AstraZeneca Pharma India Limited (AZPIL), highlighted that this expansion in Chennai signifies AstraZeneca’s unwavering commitment to pioneering science and innovation.

According to Dr. Panchal, India has a rich talent pool and a dynamic ecosystem for digital advancements, making it a pivotal hub for their global operations.

This strategic investment underscores their dedication to improving patient outcomes through cutting-edge technology and reinforces their aspiration to transform the future of the healthcare industry.

He expressed immense pride in his team’s achievements and excitement for the future as they continue to harness science to bring life-changing medicines to patients worldwide.

Since its inception, the GITC in Chennai has evolved from providing traditional IT services to becoming an engine of AstraZeneca’s digital journey, driving productivity, simplification, technology delivery, and innovation across the company’s global operations, thereby supporting the delivery of life-changing medicines to patients worldwide.

The facility currently occupies 334,000 square feet of office space at Ramanujan IT City, with plans to add approximately 180,000 square feet over the next six months to accommodate this expansion, creating AstraZeneca’s biggest global capability centre.

AstraZeneca is focused on transforming healthcare for millions of people in India.

 In addition to its innovative portfolio in specialist disease areas including oncology, cardiovascular, respiratory, and rare diseases, the company has a strong hub for technology as well as research and development in India.

Including the GITC, it employs more than 4,000 individuals in the country and is continuously shaping talent that is skilled, diverse, and future-ready.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook

Newer Post

Thumbnail for AstraZeneca to invest US$30M in Chennai expansion

JKCI attracts patients from across Africa and Europe, expanding medical tourism

Older Post

Thumbnail for AstraZeneca to invest US$30M in Chennai expansion

Pulmonary Hypertension’s impact amplified in developing nations

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.